Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas~* Metastatic disease~* Received at least two prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease.~* At least one of the prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease must have contained gemcitabine and have met the following criteria:~* Completed at least one cycle of the treatment~* Received gemcitabine administered at a minimum dose of 800 mg/m2 per week in the first cycle of treatment~* Progressed while receiving this gemcitabine regimen or within 3 months of completing gemcitabine~* Progression was documented,~* Preferentially radiologically by tumor growth or new lesions, or by~* Clear symptomatic deterioration supported by at least two of the following clinical criteria: ≥ 10% worsening in KPS or ≥ 1 worsening in ECOG; increasing weakness or fatigue; progressive weight loss; new/worsening pain requiring increased pain medication; new/worsening jaundice, nausea, or vomiting; new/worsening ascites or pleural effusions; other physical or laboratory findings consistent with disease progression.~* KPS \>/= 70~* Adequate bone marrow function~* Adequate hepatic function~* Adequate renal function~Exclusion Criteria:~* CNS metastatic disease~* Bulky disease (any single mass \>10 cm).~  -\>Grade 2 nausea or vomiting, and/or signs of intestinal obstruction.~* Prior external beam irradiation to a field that includes more than 30% of the red bone marrow.~* Patients with clinically significant severe cardiorespiratory disease.~Please consult with the clinical trial site for the full detailed list of specific inclusion/exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A IMMU-107 and gemcitabine (Type: EXPERIMENTAL): IMMU-107 and low dose gemcitabine
- Arm B Placebo and low dose gemcitabine (Type: ACTIVE_COMPARATOR): Placebo and low dose gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).